secwatch.observer — SEC 8-K summary
======================================

Issuer:     uniQure N.V. (QURE)
CIK:        0001590560
Form:       8-K
Filed at:   2024-07-23T23:59:59+00:00
Accession:  0001558370-24-009957
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

uniQure closes sale of Lexington facility to Genezen for $25M; $40M annual cash burn savings
--------------------------------------------------------------------------------

- Sold Lexington, MA manufacturing facility to Genezen for $12.5M in Series C stock and $12.5M convertible note (total $25M).
- Prepaid $50M of $100M Hercules debt; remaining $50M matures Jan 2027; expects $40M annual reduction in cash burn.
- COO Pierre Caloz exits as role eliminated; Amin Abujoub appointed Chief Technical Operations Officer.
- CEO Matt Kapusta joins Genezen board; Genezen to supply HEMGENIX under commercial supply agreement.
- Transaction closed July 22, 2024; uniQure becomes meaningful shareholder in Genezen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590560/000155837024009957/0001558370-24-009957-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590560/000155837024009957/qure-20240722x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-009957

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer